背景:在持续的COVID-19爆发期间,口罩的使用越来越多,成为我们日常生活的一部分。穿着时,长时间的接触和微环境变化深刻地导致痤疮发作,定义为“maskne”。\"
目的:我们旨在评估蜗牛分泌滤液的疗效和安全性,金盏花,和甘草根提取物组合血清(SCGS)治疗面膜。
方法:这是一个随机的,双盲,安慰剂对照试验研究。这项研究招募了66名轻度至中度掩模的参与者。SCGS和安慰剂被随机分配给参与者,每天两次使用,持续12周。痤疮病变计数的百分比变化,研究人员全球评估痤疮(IGEA),皮脂水平,角膜测量水平,经皮水分流失(TEWL),Visia®红斑评分,和不良事件在基线至第12周每周4次评估。在第12周,所有参与者使用10点视觉模拟量表(VAS)评估他们的满意度得分。
结果:在遮罩覆盖区域,在所有时间点,治疗组炎性痤疮病灶的减少百分比均显著大于安慰剂组(炎性病灶百分比变化系数=-33.89[95%CI-65.24,-2.53];p=0.03).此外,对同时使用痤疮治疗的参与者进行的亚组分析显示出类似的结果(12名参与者,系数=-50.30[95%-88.65,-11.95];p=0.01)。然而,非炎性病变无显著差异,所有的皮肤生物物理学,和群体之间的VAS。两组的不良事件均较轻,仅发生在少数病例中。
结论:SCGS可显著改善炎性痤疮病变,并具有良好的耐受性,提示其在maskne中作为辅助治疗的作用。
BACKGROUND: During the ongoing COVID-19 outbreak, face mask use has increased and became a part of our daily lives. While wearing, prolonged contact time and microenvironmental change profoundly lead to an acne flare-up, defined as \"
maskne.\"
OBJECTIVE: We aimed to assess the efficacy and safety of snail secretion filtrate, Calendula officinalis, and Glycyrrhiza glaba root extract combination serum (SCGS) in treating the
maskne.
METHODS: This was a randomized, double-blind, placebo-controlled trial study. This study enrolled 66 participants with mild-to-moderate
maskne. The SCGS and placebo were randomly assigned for participants to use twice daily for 12 weeks. Percentage change of acne lesion count, acne severity by Investigator Global Evaluation Acne (IGEA), sebum levels, corneometry levels, transepidermal water loss (TEWL), erythema score by Visia®, and adverse events were evaluated 4-weekly at baseline to Week 12. At Week 12, all participants evaluated their satisfaction scores using a 10-point visual analog scale (VAS).
RESULTS: In the mask-covered area, the percent reduction in inflammatory acne lesions from the treatment group was significantly greater than the placebo group at all time points (coefficient of percentage change of inflammatory lesions = -33.89 [95% CI -65.24, -2.53]; p = 0.03). Also, a subgroup analysis with participants using concurrent acne treatments revealed similar results (12 participants, coefficient = -50.30 [95% -88.65, -11.95]; p = 0.01). However, there were no significant differences in non-inflammatory lesions, all skin biophysics, and VAS between groups. Adverse events were mild and occurred in a few cases in both groups.
CONCLUSIONS: The SCGS could significantly improve inflammatory acne lesions and had a favorable tolerability profile, suggesting its role as an adjunctive treatment in
maskne.